Q2 2024

Filed Aug 1, 2024 · 10-Q · 32 days after period end · 0000950170-24-089241

Q2 2024 · 10-Q

Revenue

$3.50M

— vs Q2 2023

Net Income

-$68.06M

N/M vs Q2 2023

EPS Diluted

-$0.80

N/M vs Q2 2023

Operating Income-$74,216,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Revenue	$3.50M	$0.00	—	$379.00K
Net Income	-$68.06M	-$44.62M	-$37.57M	-$22.91M
EPS Diluted	-$0.80	-$0.64	-$0.62	-$0.44

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR